J&J Gains Next-Gen CoStar Stent Through $1.4 Bil. Conor Purchase
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson hopes that its $1.4 bil. purchase of next-generation drug-eluting stent developer Conor Medsystems will help it retain top-tier market share as a flurry of new competitors joins the market
You may also be interested in...
Failure Of J&J/Conor’s CoStar Stent Trial Sets Program Back Up To Four Years
Johnson & Johnson's Conor Medsystems unit will discontinue development of its CoStar paclitaxel-eluting coronary stent and terminate sales of the device overseas following the failure of the firm's CoStar II U.S. pivotal study
Failure Of J&J/Conor’s CoStar Stent Trial Sets Program Back Up To Four Years
Johnson & Johnson's Conor Medsystems unit will discontinue development of its CoStar paclitaxel-eluting coronary stent and terminate sales of the device overseas following the failure of the firm's CoStar II U.S. pivotal study
J&J Medical Device Revenue Up, But Cypher Sales Are Still A Drag
Johnson & Johnson's device revenue growth is still hindered by declining sales of the Cypher sirolimus-eluting coronary stent, the company reported during its first-quarter earnings call April 17
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: